TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03012009

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: full ablative CO2 laser
Description: ablation to the level of de dermal papilla

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional ablative CO2 laser
Description: 180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED lamp
Description: peak wavelength 630 nm, 37J/cm2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED lamp
Description: peak wavelength 630 nm, 37J/cm2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride 2% with epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride 2% with epinephrine
Study: NCT04905966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education and Physical activity intervention
Description: Schools randomized to the experimental group received nutrition education sessions and physical activity classes.
Study: NCT04783818

Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: PMRT

Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: PMRT

Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: PMRT
Study: NCT02925117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study: NCT03909646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram
Description: A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: 5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical excision
Description: Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
Study: NCT02885207

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Focal epilepsy of unknown cause
Description: Male or female 18-65 years presenting focal epilepsy on the following arguments:~* Crisis with clinical symptoms indicating focal seizure~* \& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~* No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~* No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~* No argument for metabolic or neurodegenerative genetic epilepsy.~* Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines).
Study: NCT02663908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Study: NCT01593085

Intervention type: BEHAVIORAL
Intervention: interview with a doctor for evaluating suicide risk
Description: patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~--------------------------------------------------------------------------------
Study: NCT02487433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib MR 22 mg (Fed)
Description: A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib MR 22 mg (Fasted)
Description: A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
Study: NCT01932359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rapidly absorbable suture (Vicryl Rapide)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-absorbable suture (Ethilon)
Study: NCT03598543

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, this is an obervational study.

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, this is an obervational study.
Study: NCT01269411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative
Study: NCT02957929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single oral dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single oral dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single oral dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single oral dose fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single oral dose fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 multiple oral doses 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 multiple oral doses 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 multiple oral doses 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochrome P450 substrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo control
Study: NCT04727073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Spironolactone
Description: Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
Study: NCT02259101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I Treatment Condition
Description: Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SH Comparison Condition
Description: Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
Study: NCT02819739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical oxygen
Study: NCT03798197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg estetrol (E4)
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg estetrol (E4)
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
Study: NCT02077478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol administration using TCI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol administration using MCI
Study: NCT01788228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: 2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: 2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
Study: NCT00601198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
Study: NCT02261454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum chewing
Description: 1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
Study: NCT00270439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of omentum
Description: patients with type 2 diabetes had their omentum removed
Study: NCT01153074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closure of bronchopleural fistula with Occlutech Figulla
Description: Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
Study: NCT00370071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
Study: NCT02272075

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile OCT M3 scope
Study: NCT02310763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06252616
Description: PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
Study: NCT01932307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck strengthening exercise program
Description: Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
Study: NCT02310763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02738827

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser treatment
Description: Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
Study: NCT02221063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thiamin fortified fish sauce (low concentration)
Description: Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
Study: NCT00870948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
Study: NCT02762578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Twice daily subcutaneous (sc, under the skin) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: Twice daily subcutaneous (sc, under the skin) injection.
Study: NCT04456257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional picosecond 1,064 nm laser
Description: The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
Study: NCT00508755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Robot
Description: gait training with the use of a gait robot

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Neuromuscular stimulation with intramuscular electrodes
Description: gait training with use of functional electrical stimulation
Study: NCT00870948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
Study: NCT01765907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Study: NCT00833235

Intervention type: OTHER
Intervention: Artificial Tears
Description: Artificial tears (any brand) may be used to treat dry eye symptoms.

Intervention type: OTHER
Intervention: Artificial Tears
Description: Artificial tears (any brand) may be used to treat dry eye symptoms.
Study: NCT04478266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amcenestrant-matching placebo
Description: Pharmaceutical form: Tablets Route of Administration: Oral
Study: NCT00337467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir + Ritonavir
Description: Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
Study: NCT02520804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sterofundin
Description: sterofundin for shock patients in the first 72 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Normal saline for shock patients in the first 72 hours
Study: NCT05267353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention program
Description: It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention.
Study: NCT02221063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thiamin fortified fish sauce (higher concentration)
Description: Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fish sauce
Description: Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
Study: NCT02761603

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Practice-centered Instruction (HAPI)
Description: Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi (CHI)
Description: Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
Study: NCT03907241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octanorm 16.5%
Description: Human normal immunoglobulin
Study: NCT01752530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer program C8
Description: Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual at the clinic

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual at the clinic
Study: NCT04869371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: 75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Pamoate for Injectable Suspension
Description: 15mg every 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate for Injectable Suspension
Description: 15mg every 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Acetate Tablets
Description: 5 mg oral low dose prednisone, once daily
Study: NCT02209116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qb Test
Description: Given to all participants but the results will be open or blind depending on arm allocation

Intervention type: OTHER
Group type: OTHER
Intervention: Qb Test
Description: Given to all participants but the results will be open or blind depending on arm allocation
Study: NCT01937351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pantheris System
Description: Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
Study: NCT02872051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBBIS mental health care and standard vocational rehabilitation
Description: Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated mental health care and vocational rehabilitation
Description: Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element
Study: NCT02289937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively